• Molecular NameEpoprostenol
  • SynonymPGI2; Prostacyclin; Prostaglandin I2
  • Weight352.471
  • Drugbank_IDDB01240
  • ACS_NO35121-78-9
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.19
  • pkaN/A
  • LogD (pH=7, predicted)1.09
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.19
  • LogSw (predicted, AB/LogsW2.0)0.3
  • Sw (mg/ml) (predicted, ACD/Labs)1.26
  • No.of HBond Donors3
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds10
  • TPSA86.99
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA member of the family of lipid molecules known as eicosanoids.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmEpoprostenol is metabolized to 2 primary metabolites: 6-keto-PGF1alpha?formed by spontaneous degradation) and 6,15-diketo-13,14-dihydro-PGF1alpha (enzymatically formed), both of which have pharmacological activity orders of magnitude less than epoprostenol in animal test systems. Fourteen additional minor metabolites have been isolated from urine, indicating that epoprostenol is extensively metabolized in humans.
  • Half lifeThe in vitro half-life of epoprostenol in human blood at 37°C and pH 7.4 is approximately 6 minutes; the in vivo half-life of epoprostenol in humans is therefore expected to be no greater than 6 minutes.
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of epoprostenol. Single intravenous doses at 10 and 50 mg/kg (2703 and 27,027 times the recommended acute phase human dose based on body surface area) were lethal to mice and rats, respectively. Symptoms of acute toxicity were hypoactivity, ataxia, loss of righting reflex, deep slow breathing, and hypothermia.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A